Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edge Therapeutics Inc.

Division of PDS Biotechnology Corp.
www.edgetherapeutics.com

Latest From Edge Therapeutics Inc.

Deal Watch: PDS And Edge Merge To Progress HPV-Linked Cancer Immunotherapy

Immunotherapy firms Edge and PDS announce planned merger, while Telix advances its prostate cancer strategy by acquiring ANMI. Kyowa Hakko Kirin is signed up to distribute GlaxoSmithKline's Phase III CKD-associated anemia product daprodustat in Japan.

Deals M & A

Pipeline Watch: Phase III Trials Initiated For AMT-061, RP-G28 And APL-2

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Pipeline Watch: Phase III Starts With Murepavadin, CSL112 And Vibegron

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Edge 'Devastated' By Phase III Failure of EG-1962, Set To Downsize

Company announces plans for layoffs after Phase III NEWTON 2 study of EG-1962 for subarachnoid hemorrhage goes up in smoke.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PDS Biotechnology Corp.
  • Senior Management
  • Brian A Leuthner, Pres. & CEO
    Andrew Saik, CFO
    Herbert J Faleck, DO, CMO
  • Contact Info
  • Edge Therapeutics Inc.
    Phone: (800) 208-3343
    300 Connell Dr.
    Ste. 4000
    Berkeley Heights, NJ 07922
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register